Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2350MR)

This product GTTS-WQ2350MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2350MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5432MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ15904MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ8781MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ7262MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ10042MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA L19-131 I
GTTS-WQ5700MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ11638MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ2789MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-282
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW